Ltbp2 as a biomarker for renal dysfunction
AssigneePronota N.V.
InventorKoen Kas
Life of this patent
Estimating the term…
Abstract
The application discloses LTBP2 as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.
Claims34
A method for diagnosing, predicting, prognosticating and/or monitoring renal dysfunction in a subject, wherein the examination phase of the method comprises measuring the quantity of latent transforming growth factor beta binding protein 2 (LTBP2) in a sample from the subject.
A method for determining glomerular filtration rate (GFR) of a subject comprising measuring the quantity of LTBP2 in a sample from said subject and converting said measured quantity of LTBP2 to GFR of said subject.
A method to determine whether a subject is or is not (such as, for example, still is, or is no longer) in need of a therapy to treat renal dysfunction, comprising:
- (i) measuring the quantity of LTBP2 in the sample from the subject;
- (ii) comparing the quantity of LTBP2 measured in (i) with a reference value of the quantity of LTBP2, said reference value representing a known diagnosis, prediction and/or prognosis of renal dysfunction or normal renal function;
- (iii) finding a deviation or no deviation of the quantity of LTBP2 measured in (i) from said reference value;
- (iv) inferring from said finding the presence or absence of a need for a therapy to treat renal dysfunction.
A method for predicting or prognosticating mortality in a subject having dyspnea and/or acute heart failure and/or renal dysfunction, comprising measuring the quantity of LTBP2 in a sample from said subject.
A method for predicting, diagnosing, prognosticating and/or monitoring any one of left ventricular hypertrophy (LVH), cardiac fibrosis (CF), preeclampsia (PE) and pregnancy-associated proteinuria (PAP), comprising measuring LTBP2 levels in a sample from said subject.
A testing device capable of measuring the quantity of LTBP2 in a sample from a subject comprising:
- (i) means for measuring the quantity of LTBP2 in said sample, and
- (ii) means of storing the reference value in the device, and
- (iii) means of comparing the obtained quantity with the stored reference value, and
- (iv) means for visualising the quantity of LTBP2 measured in the sample.
A screening assay to select, from a group of test agents, a candidate agent potentially useful in the treatment of renal dysfunction selected from the group consisting of:
- acute renal failure or acute kidney injury-, chronic renal failure or chronic kidney disease, renal fibrosis, nephronophthisis, bilateral renal artery stenosis, ischemic nephropathy, haemolytic-uremic syndrome and vasculitis, and further focal segmental nephrosclerosis, glomerulosclerosis, glomerulonephritis, IgA nephritis, diabetic nephropathy, lupus nephritis, polycystic kidney disease, chronic tubulointerstitial nephritis (e.g., drug and/or toxin-induced), kidney stones, and renal disease caused by prostate diseases, said assay comprising determining whether a tested agent can modulate, such as increase or reduce and preferably reduce, the level and/or activity of LTBP2.
A method of treating renal dysfunction selected from the group consisting of:
- acute renal failure or acute kidney injury, chronic renal failure or chronic kidney disease, renal fibrosis, nephronophthisis, bilateral renal artery stenosis, ischemic nephropathy, haemolytic-uremic syndrome and vasculitis, and further focal segmental nephrosclerosis, glomerulosclerosis, glomerulonephritis, IgA nephritis, diabetic nephropathy, lupus nephritis, polycystic kidney disease, chronic tubulointerstitial nephritis (e.g., drug and/or toxin-induced), kidney stones, and renal disease caused by prostate diseases, using LTBP2 as a medicament.
Dependencies are inferred from the claim text.